The resulting regimen of multiple injections of rapid-acting insulin with basal insulin (MDI) achieves target glycaemia in only 70 % of patients, the remaining corresponding to MDI failure.3 As an alternative, glucagon-like peptide-1 (GLP-l)-receptor agonists should be combined with basal insulin, this association thus providing equal efficacy compared with the combined basal bolus strategy and giving other advantages, such as weight loss and reduction of the hypoglycaemia rate.4–7 The use of external pumps in patients with T2D is a recent practice compared with that in type 1 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.